Evolving Understanding of the CLL Genome

Seminars in Hematology

Volumn 51, Issue 3, 2014, Pages 177-187

  Gruber, Michaela ^a,b,c   Wu, Catherine J ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB;

ARTICLE; ASYMPTOMATIC DISEASE; B LYMPHOCYTE; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CELL CLONING; CHRONIC LYMPHATIC LEUKEMIA; DEVELOPMENTAL STAGE; DISEASE COURSE; DNA MODIFICATION; EPIGENETICS; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; LEUKEMIA RELAPSE; LEUKEMOGENESIS; LYMPHOCYTE SUBPOPULATION; MOLECULAR EVOLUTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CHROMOSOME ABERRATIONS; EPIGENOMICS; GENETIC HETEROGENEITY; GENOME; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84904411900     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.05.004     Document Type: Article

References (83)

1. Oscier D., Dearden C., Erem E., et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 2012, 159:541-564.
2. Rossi D., Rasi S., Spina V., et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013, 121:1403-1412.
3. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219-234.
4. Binet J.L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48:198-206.
5. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
6. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
7. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
8. Puente X.S., Pinyol M., Quesada V., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
9. Wang L., Lawrence M.S., Wan Y., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011, 365:2497-2506.
10. Schuh A., Becq J., Humphray S., et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 2012, 120:4191-4196.
11. Fabbri G., Rasi S., Rossi D., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011, 208:1389-1401.
12. Fabbri G., Khiabanian H., Holmes A.B., et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013, 210:2273-2288.
13. Landau D.A., Carter S.L., Stojanov P., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152:714-726.
14. Ramsay A.J., Quesada V., Foronda M., et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet 2013, 45:526-530.
15. Quesada V., Conde L., Villamor N., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012, 44:47-52.
16. Ngo V.N., Young R.M., Schmitz R., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
17. Treon S.P., Xu L., Yang G., et al. MYD88 L265P somatic mutation in Waldenstrom[U+05F3]s macroglobulinemia. N Engl J Med 2012, 367:826-833.
18. Arruga F., Gizdic B., Serra S., et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 2014, 28:1060-1070.
19. Wan Y., Wu C.J. SF3B1 mutations in chronic lymphocytic leukemia. Blood 2013, 121:4627-4634.
20. Wan Y., Brooks A., Wang L., et al. SF3B1 mutation alters the selection of 3[U+05F3] RNA splice sites in chronic lymphocytic leukemia. Blood 2013, 122:117.
21. Ferreira P.G., Jares P., Rico D., et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res 2014, 24:212-226.
22. Jeromin S., Weissmann S., Haferlach C., et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014, 28:108-117.
23. Lapalombella R., Sun Q., Williams K., et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012, 120:4621-4634.
24. Rossi D., Fangazio M., Rasi S., et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012, 119:2854-2862.
25. Cortese D., Sutton L.A., Cahill N., et al. On the way towards a [U+05F3]CLL prognostic index[U+05F3]: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia 2014, 28:710-713.
26. Weissmann S., Roller A., Jeromin S., et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013, 27:2393-2396.
27. Oscier D.G., Rose-Zerilli M.J., Winkelmann N., et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013, 121:468-475.
28. Rossi D., Bruscaggin A., Spina V., et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011, 118:6904-6908.
29. Rossi D., Rasi S., Fabbri G., et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012, 119:521-529.
30. Messina M., Del Giudice I., Khiabanian H., et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood 2014, 123:2378-2388.
31. Bea S., Lopez-Guillermo A., Ribas M., et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter[U+05F3]s syndrome). Am J Pathol 2002, 161:957-968.
32. Shanafelt T.D., Hanson C., Dewald G.W., et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 2008, 26:e5-e6.
33. Shanafelt T.D., Witzig T.E., Fink S.R., et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006, 24:4634-4641.
34. Braggio E., Kay N.E., VanWier S., et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 2012, 26:1698-1701.
35. Shen H., Laird P.W. Interplay between the cancer genome and epigenome. Cell 2013, 153:38-55.
36. Ziller M.J., Gu H., Muller F., et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 2013, 500:477-481.
37. Rahmatpanah F.B., Carstens S., Hooshmand S.I., et al. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics 2009, 1:39-61.
38. Kanduri M., Cahill N., Goransson H., et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010, 115:296-305.
39. Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J.C. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82:1820-1828.
40. Yuille M.R., Condie A., Stone E.M., et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer 2001, 30:336-341.
41. Raval A., Tanner S.M., Byrd J.C., et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007, 129:879-890.
42. Cahill N., Bergh A.C., Kanduri M., et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 2013, 27:150-158.
43. Baer C., Claus R., Frenzel L.P., et al. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res 2012, 72:3775-3785.
44. Garding A., Bhattacharya N., Claus R., et al. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB. PLoS Genet 2013, 9:e1003373.
45. Kulis M., Heath S., Bibikova M., et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012, 44:1236-1242.
46. Landau D.A., Clement K., Boyle P., et al. Increased local disorder of DNA methylation forms the basis of high intra-leukemic epigenetic heterogeneity and enhances CLL evolution. Blood 2013, 122:596.
47. Oakes C.C., Claus R., Gu L., et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov 2014, 4:348-361.
48. Pospisilova S., Gonzalez D., Malcikova J., et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012, 26:1458-1461.
49. Zenz T., Eichhorst B., Busch R., et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010, 28:4473-4479.
50. Schnaiter A., Paschka P., Rossi M., et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013, 122:1266-1270.
51. Puente X.S., Lopez-Otin C. The evolutionary biography of chronic lymphocytic leukemia. Nat Genet 2013, 45:229-231.
52. Rossi D., Khiabanian H., Spina V., et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014, 123:2139-2147.
53. Groth C., Fortini M.E. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 2012, 23:465-472.
54. Bonnal S., Vigevani L., Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012, 11:847-859.
55. Ruden M., Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013, 39:444-456.
56. Alexandrov L.B., Nik-Zainal S., Wedge D.C., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
57. Lawrence M.S., Stojanov P., Polak P., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
58. Lamont K.R., Hasham M.G., Donghia N.M., et al. Attenuating homologous recombination stimulates an AID-induced antileukemic effect. J Exp Med 2013, 210:1021-1033.
59. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
60. Niemann C.U., Jones J., Wiestner A. Towards targeted therapy of chronic lymphocytic leukemia. Adv Exp Med Biol 2013, 792:259-291.
61. Bea S., Valdes-Mas R., Navarro A., et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013, 110:18250-18255.
62. Okosun J., Bodor C., Wang J., et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014, 46:176-181.
63. Love C., Sun Z., Jima D., et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012, 44:1321-1325.
64. Richter J., Schlesner M., Hoffmann S., et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012, 44:1316-1320.
65. Schmitz R., Young R.M., Ceribelli M., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
66. Pasqualucci L., Trifonov V., Fabbri G., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011, 43:830-837.
67. Rossi D., Trifonov V., Fangazio M., et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012, 209:1537-1551.
68. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
69. Lohr J.G., Stojanov P., Carter S.L., et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014, 25:91-101.
70. Lawrence M.S., Stojanov P., Mermel C.H., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
71. Stephens P.J., Greenman C.D., Fu B., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
72. Baca S.C., Prandi D., Lawrence M.S., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153:666-677.
73. Kotliar D., Landau D.A., Litvin O., et al. Reconstructing a genotype-phenotype map in chronic lymphocytic leukemia. Blood 2013, 122:2857.
74. Method of the year 2013. Nat Methods 2014, 11:1.
75. Berndt S.I., Skibola C.F., Joseph V., et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet 2013, 45:868-876.
76. Speedy H.E., Di Bernardo M.C., Sava G.P., et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2014, 46:56-60.
77. Clifford R., Louis T., Robbe P., et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 2014, 123:1021-1031.
78. Calin G.A., Ferracin M., Cimmino A., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
79. Mansouri L., Cahill N., Gunnarsson R., et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 2013, 27:512-514.
80. Gonzalez D., Martinez P., Wade R., et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011, 29:2223-2229.
81. Zenz T., Habe S., Denzel T., et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009, 114:2589-2597.
82. Balatti V., Bottoni A., Palamarchuk A., et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012, 119:329-331.
83. Zenz T., Vollmer D., Trbusek M., et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010, 24:2072-2079.